secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncology Institute, Inc. (TOI)
CIK:        0001799191
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001628280-23-017224
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncology Institute Q1 revenue $76M (+38% YoY) but net loss $30M, EBITDA loss widens
--------------------------------------------------------------------------------

- Revenue of $76M, up 38.1% YoY; gross profit $14M (18.5% margin, down from 22.3%).
- Net loss of $30M ($0.33 diluted loss) vs net income of $19.3M ($0.22 EPS) in Q1 2022.
- Adjusted EBITDA loss of $7.9M vs loss of $5.2M in prior year; cash of $114M.
- Patient visits up 17% YoY; oral drugs dispensed up 34% YoY.
- New value-based contracts in CA and TX; Florida gainshare shows >50% referral capture and >30% cost savings; Q3 guidance reaffirmed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799191/000162828023017224/0001628280-23-017224-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799191/000162828023017224/toi-20230510.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-017224

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer